PSivida Corp. secures Poland marketing nod for eye disease treatment
pSivida Corp. ( NASDAQ:PSDV) has been granted marketing authorisation for its ILUVIEN eye disease treatment in Poland.
This marks the completion of the latest round of European Union authorisations with the treatment for vision impairment associated with diabetic macular edema now approved in 17 countries.
ILUVIEN is currently being sold in the U.S. UK Germany and Portugal.
pSivida is entitled to 20 percent of net profits of ILUVIEN sales by its licensee on a country-by-country quarter-by-quarter basis.
Proactive Investors Australia is the market leader in producing news articles and research reports on ASX emerging companies with distribution in Australia UK North America and Hong Kong / China.
Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.